Characterization of Teicoplanin-Specific T-Cells from Drug Naïve Donors Expressing HLA-A*32:01.

Gardner, Joshua, Ogese, Monday ORCID: 0000-0002-1873-4032, Betts, Catherine J, Pirmohamed, Munir ORCID: 0000-0002-7534-7266 and Naisbitt, Dean J (2022) Characterization of Teicoplanin-Specific T-Cells from Drug Naïve Donors Expressing HLA-A*32:01. Chemical research in toxicology, 35 (2). pp. 199-202.

Access the full-text of this item by clicking on the Open Access link.

Text
Teicoplanin CRT Rapid Report 24.01.22.docx - Author Accepted Manuscript
Download (496kB)

Official URL: http://dx.doi.org/10.1021/acs.chemrestox.1c00425

Abstract

Teicoplanin is a glycopeptide antibiotic deployed to combat Gram-positive bacterial infection and has recently been associated with development of adverse drug reactions, particularly following previous exposure to vancomycin. In this study, we generated teicoplanin-specific monoclonal T-cell populations from healthy volunteers expressing HLA-A*32:01 and defined pathways of T-cell activation and HLA allele restriction. Teicoplanin-responsive T-cells were CD8+, HLA class I-restricted, and cross-reacted with the lipoglycopeptide daptomycin in proliferation and cytokine/cytolytic molecule (granzyme B, Perforin, and FasL) release assays. These data show that teicoplanin activates T-cells, which may play a role in the pathogenesis of teicoplanin-induced adverse events, in HLA-A*32:01 positive donors.

Item Type:	Article
Uncontrolled Keywords:	T-Lymphocytes, Humans, Teicoplanin, HLA-A Antigens, Anti-Bacterial Agents, Healthy Volunteers
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	30 Mar 2022 09:18
Last Modified:	18 Jan 2023 21:06
DOI:	10.1021/acs.chemrestox.1c00425
Open Access URL:	https://doi.org/10.1021/acs.chemrestox.1c00425
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3151745